According to the statistics of the Oriental Wealth Network Data Center, as of December 19, more than 60 listed companies have disclosed their 2022 annual performance forecasts, and the overall view is mixed
.
From the perspective of the year-on-year growth of net profit, 7 of the listed companies are expected to double their net profit in 2022, namely Shanwaishan, KONE Technology, Chuanning Biotechnology, Dalian Heavy Industry, Shangtai Technology, Jardine Jiaye, Weihai Guangtai, these companies with bright net profits are mainly concentrated in technology, machinery, medicine and biology industries
.
In the pharmaceutical and biological industry, there are 2 companies that are expected to double their net profit in 2022, namely Jardine Jardine Jiaye and Chuanning Biotechnology
.
Among them, Jardine Jardine is expected to expect a net profit attributable to shareholders of listed companies from January to December 2022 of 351 million yuan to 407 million yuan, an increase of 140.
85% to 179.
67% over the previous year; The net profit after deducting non-recurring profit and loss from January to December 2022 was 342 million yuan to 390 million yuan, an increase of 152.
73% to 188.
64%
over the previous year.
According to the data, Jardine Jardine Jiaye is a domestic household ventilator head enterprise, the company has developed a full range of medical products around the field of respiratory health, and has preliminarily completed the construction of a household, medical, consumables and chronic disease management platform in this field to meet the full-cycle, multi-scenario and systematic health needs
of patients.
At the same time, the company continues to strengthen R&D investment, laying the foundation
for the iterative upgrading of new products around functionality, comfort and ease of use, as well as the expansion of new fields such as oxygen concentrators and atomizers.
The company said on the interactive platform on December 8 that after the release of 20 policies, the company and its products (household non-invasive ventilators, ventilation masks, high-flow humidified oxygen therapy instruments, oxygen generators, etc.
) have attracted high attention from the market, and the company responded to policy guidance, continued to pay attention to the development of the epidemic, combined with its own product characteristics, and provided non-invasive mechanical ventilation solutions and oxygen therapy product solutions
for the market in a targeted manner.
The company has a rich product category, which can meet the needs of epidemic prevention and control and daily life in multiple scenarios, and provide multiple health protection and support
.
Huaan Securities recently released a research report that the household ventilator equipment and consumables market development prospect is good, high entry barriers, high market concentration, the company's brand value is beginning to take shape, market share has several times room for improvement, at the same time, the company's product portfolio is diverse, research and development strength is outstanding, new products are constantly upgraded, and the moat continues to be strengthened, considering the wide application space of ventilator treatment in the field of respiratory sleep diseases dominated by COPD and OSA, as well as the company's potential and cost-effective advantages as a Chinese brand to go overseas in the global market, covering for the first time , with a "buy" rating
.
Chuanning Biotech expects the net profit attributable to shareholders of listed companies in 2022 to be 382 million yuan to 411 million yuan, an increase of 243% to 269% over the previous year; Net profit after deducting non-recurring profit and loss is expected to be RMB420 million to RMB450 million in 2022, an increase of 132% to 149%
year-on-year.
As for the reasons for the growth in performance, Chuanning Biotech said that due to the high sales price of the company's main products, the business performance showed a stable growth trend
.
In the fourth quarter of 2021, the issuer suspended production due to the epidemic, resulting in a relatively low profit level in 2021, and the company's main product prices in 2022 are expected to show an upward trend compared with the same period last year, of which the average selling price of erythromycin thiocyanate is expected to increase by about 18%, the average sales unit price of 6-APA is expected to increase by about 41%, and penicillin G potassium salt is expected to increase by about 63%, and in the case of a slight increase in overall sales, it is expected that the net profit for the whole year will increase significantly compared with 2021
。
According to the data, Chuanning Biotechnology is the core enterprise in the field of antibiotic intermediates and one of the main antibiotic intermediates production bases in China, and its products have a complete range of antibiotic intermediates, covering the main intermediates
of macrolides and broad-spectrum antibiotics.
Recently, the prospectus disclosed by Chuanning Biotechnology shows that the company plans to raise 600 million yuan, part of which will be used for the construction project of Shanghai Research Institute, after the completion of the project, it will improve the company's R&D strength to a certain extent, shorten the R&D cycle of the products to be developed, and accelerate the company's R&D layout in the antibiotic intermediates, high-value-added natural products, biopesticides, animal health products, degradable bio-based new materials and other categories of pharmaceutical intermediates.
Better adapt to the future market development and customer needs
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
